RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis
RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis
复制标题
DOI：
10.1016/j.peptides.2004.09.018
复制
发表时间：
2005-02-01
期刊：
影响因子：
3
通讯作者：
Scalise, G
中科院分区：
文献类型：
--
作者：
Giacometti, A;Cirioni, O;Scalise, G
RNAIII抑制肽（RIP，YSPWTNF-NH 2）是一种群体感应肽抑制剂，可防止金黄色葡萄球菌毒素产生和生物膜形成。使用小鼠脓毒症模型来测试RIP单独或与常规抗生素组合抑制S.金黄色葡萄球菌引起的脓毒症小鼠静脉注射3.0 × 10（6）CFU的S。金黄色葡萄球菌ATCC 25923或3.0 x 10（6）CFU的S.金黄色葡萄球菌Smith弥散型。所有动物随机接受静脉内等渗氯化钠溶液作为对照，或20 mg/kg RIP单独或与20 mg/kg头孢唑林联合给药。10 mg/kg亚胺培南。或10 mg/kg万古霉素。主要结果指标为菌血症和致死率。与对照相比，所有化合物的致死率均降低。尽管一般而言，联合给药组的细菌计数显著低于单药组，但仅RIP和万古霉素联合给药组（相对于头孢唑林）的致死率在统计学上显著降低。最低致死率（10%）和菌血症（
RNAIII-inhibiting peptide (RIP, YSPWTNF-NH2) is a quorum-sensing peptide inhibitor that prevents Staphylococcus aureus toxin production and biofilm formation. A mouse sepsis model was used to test the efficacy of RIP alone or in combination with conventional antibiotics in suppressing S. aureus-induced sepsis. Mice were injected intravenously with 3.0 x 10(6) CFU of S. aureus ATCC 25923 or with 3.0 x 10(6) CFU of S. aureus strain Smith diffuse. All animals were randomized to receive intravenously isotonic sodium chloride solution as a control, or 20 mg/kg RIP alone or combined with 20 mg/kg cefazolin. 10 mg/kg imipenem. or 10 mg/kg vancomycin immediately or 6 h after bacterial challenge. Main outcome measures were bacteremia and lethality. All compounds reduced lethality when compared to controls. Although, in general combined-treated groups had significant lower bacterial counts when associated to singly-treated groups only the combination between RIP and vancomycin with respect to cefazolin gave a statistically, significant decrease in the lethality rate. Lowest lethality rates (10%) and bacteremia (